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Abstract
Background: Transforming growth factor beta (TGFβ) signalling is involved in both tumour suppression and
tumour progression. The mRNA expression levels of the TGFβ isoforms and receptors in breast tumours may
have prognostic value and clinical implications.
Methods: The mRNA levels of TGFB1, TGFB2, TGFB3, TGFBR1 and TGFBR2 were analysed in primary breast tumours
and adjacent normal breast tissues, and the associations with tumour characteristics and patients’ overall and
relapse-free survival were evaluated, using the public gene expression microarray data from The Cancer Genome
Atlas (n = 520) and the Gene Expression Omnibus (four datasets) and our quantitative real-time PCR validation
data (n = 71).
Results: Significantly higher TGFB1 and TGFB3 mRNA levels and lower TGFBR2 mRNA levels were observed in
primary tumours compared with their paired normal tissues. TGFB1 mRNA expression was seemly lower in
triple-negative tumours and in tumours from lymph node-negative patients. TGFB3 mRNA expression was
significantly lower in estrogen receptor-negative/progesterone receptor-negative/Basal-like/Grade 3 tumours.
High TGFB2, TGFB3 and TGFBR2 mRNA levels in tumours were generally associated with better prognosis for
patients, especially those diagnosed with lymph node-negative diseases. High TGFBR1 mRNA levels in tumours
were associated with poorer clinical outcomes for patients diagnosed with small (diameter ≤2 cm) tumours.
Conclusions: The results indicate a reduced responsiveness of tumour cells to TGFβ, a preferential up-regulation
of TGFB1 in malignant tumours and a preferential up-regulation of TGFB3 in premalignant tumours. The results
may not only provide prognostic value for patients but also assist in classifying tumours according to their
potential responses to TGFβ and selecting patients for TGFβ signalling pathway targeted therapies.
Keywords: TGFβ, Breast cancer, mRNA expression, Prognosis
Background
Transforming growth factor beta (TGFβ) signalling is
involved in the maintenance of tissue homeostasis and
suppression of premalignant tumour cells, however,
when the regulations are circumvented, TGFβ signalling
can be advantageously exploited by the tumour cells to
promote tumour progression and metastasis [1]. Three
isoforms of TGFβ (TGFβ1, TGFβ2 and TGFβ3) all
function as secreted polypeptides that can modulate the
cellular microenvironment [2]. When activated, TGFβ
binds to and brings together transmembrane TGFβ
receptors type I (TβRI) and type II (TβRII) to form a
ligand-receptor complex that propagates the signal to
the nucleus [3]. The effects and mode of action of TGFβ
are varied and depend on the cellular context [4].
Extensive efforts have been made to investigate the
role of TGFβ signalling in the development and progres-
sion of cancer and to develop drugs targeting the TGFβ
signalling pathway for a number of cancer types,
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including breast cancer [1, 5–7]. The prognostic value of
the components of TGFβ pathway have also been ex-
plored in breast cancer, though conflicting results have
been noted [8–11]. Much of our knowledge about TGFβ
signalling in breast cancer is based on the studies char-
acterizing the proteins involved. A few pioneer studies
have evaluated the mRNA levels [12, 13], whereas
whether the mRNA levels of the key components of the
TGFβ pathway also have prognostic value and clinical
implications is inconclusive.
Here, we used the public breast cancer gene expres-
sion microarray datasets from The Cancer Genome
Atlas (TCGA) and the Gene Expression Omnibus (GEO)
to compare the mRNA expression levels of TGFB1,
TGFB2, TGFB3, TGFBR1 and TGFBR2 in primary tu-
mours and tumour-adjacent normal tissues, and to evalu-
ate the associations between the mRNA levels and the
clinical, pathological and molecular tumour characteristics
and the patients’ overall and relapse-free survival. We also
validated the gene expression profiles on an independent
set of breast cancer surgical specimens by reverse-
transcription quantitative real-time polymerase chain
reaction (RT-qPCR).
Methods
Study population and characteristics of breast cancer
specimens
The TCGA breast cancer level 3 mRNA expression
Agilent microarray data (Lowess normalized and log2-
transformed) and the patients’ clinical data were
downloaded from the Broad Genome Data Analysis
Centre Firehose (April 2015 version). The TCGA cohort
(Table 1) involved 520 untreated primary breast tumour
samples and 59 paired tumour-adjacent normal tissue
samples (taken from greater than 2.0 cm away from the
tumour) from 520 females (age range 26–90 years). The
bio-specimen collection criteria, sample processing,
clinical data quality assurance and microarray processing
had been described by TCGA previously [14]. The
pathologic stages, namely, primary tumour (T), regional
lymph nodes (N) and distant metastases (M) were made
binary in this study: tumour size was coded as “≤2 cm”
for T1, “>2 cm” for T2 and T3, and “Not Available”
(NA) for T4 and TX; involvement of regional lymph
nodes was coded as “negative” for N0, NA for NX and
“positive” for the others; distant metastasis was coded as
"positive" for M1 and "negative" for the others. Immuno-
histochemical data was used for determining estrogen
receptor (ER), progesterone receptor (PR) and human
epidermal growth factor receptor 2 (HER2) statuses.
HER2 status was supplemented by the results of fluores-
cence in situ hybridization for the “equivocal” or NA
calls. Scores of “indeterminate”, “equivocal” or “not
performed” were coded as NA. PAM50 subtypes for 513
of the tumour samples had been previously assigned
[14], and that for the other seven tumour samples were
predicted using the 50-gene PAM50 model [15].
A total of four breast cancer microarray datasets from
GEO were included in this study (Table 1). The selection
criteria were that the dataset should contain ≥200 clin-
ical specimens and there was a published paper associ-
ated with it. The Ivshina cohort (GSE4922) was of
unselected population [16]. The Schmidt (GSE11121)
and Wang (GSE2034) cohorts were both composed of
the tumour specimens from lymph node-negative pa-
tients [17, 18]. The Symmans cohort (GSE17705) was
composed of ER-positive tumour specimens [19].
The RT-qPCR validation cohort was composed of 71
tumour surgical specimens (containing >50 % tumour
cells) from 71 females (age range 33–85 years) diagnosed
with breast cancer (Table 1). Written informed consent
was obtained from all patients. Ethical approvals were
obtained from the Human Research Ethics Committee
at the University of Queensland (UQ) and Royal
Brisbane & Women’s Hospital before the study was
conducted. The tumour specimens were snap frozen after
surgery and stored in liquid nitrogen at UQ Centre for
Clinical Research (the Brisbane Breast Bank) and Wesley
hospital, Brisbane, until required for RNA extraction.
Processing of GEO datasets
The gene expression data of the four GEO datasets were
all based on Affymetrix U133A and U133A&B array sets.
The data of the probe sets 203084_at (TGFB1), 220406_at
(TGFB2), 209747_at (TGFB3), 206943_at (TGFBR1) and
208944_at (TGFBR2) from each GEO dataset and each
subset of the Ivshina dataset (stratified by tumour size,
presence or absence of regional lymph nodes and ER
status) were log2-transformed and standardized to mean =
0 and standard deviation (SD) = 1. The Ivshina cohort was
renamed as “GEO cohort, All”, which was used to repre-
sent unselected population. The log2-transformed and
standardized gene expression data of the Schmidt cohort,
the Wang cohort and the lymph node-negative subset
of the Ivshina cohort were merged to form “GEO cohort,
N neg.”; and the log2-transformed and standardized gene
expression data of the Symmans cohort and the ER-
positive subset of the Ivshina cohort were merged to form
“GEO cohort, ER pos.”. The T ≤2 cm, T >2 cm, lymph
node-positive and ER-negative subsets of the Ivshina
cohort were named as “GEO cohort, T ≤2 cm” “GEO
cohort, T >2 cm”, “GEO cohort, N pos.” and “GEO cohort,
ER neg.”, respectively. The Ivshina dataset contained
recurrence-free survival data (local, regional or distant),
while the other three datasets contained distant relapse-
free survival data. Thus the merged survival data was
referred as relapse-free survival data but with bias to more
distant relapse-free survival data.
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Table 1 Tumour characteristics of the breast cancer specimens
Cohorts TCGA TCGA-sub RT-qPCR Ivshina Schmidt Symmans Wang
N 520 59 71 249 200 298 286
Histological type
Ductal 442 (85.0) 51 (86.4) 56 (78.9) – – – –
Lobular 41 (7.9) 3 (5.1) 5 (7.0) – – – –
Mixed and others 36 (6.9) 5 (8.5) 9 (12.7) – – – –
Tumour diameter
≤2.0 cm 133 (25.6) 20 (33.9) 39 (54.9) 126 (50.6) 112 (56.0) – –
>2.0 cm 364 (70.0) 38 (64.4) 32 (45.1) 123 (49.4) 88 (44.0) – –
Regional lymph nodes
Negative 253 (48.7) 25 (42.4) 34 (47.9) 159 (63.9) 200 (100) 175 (58.7) 286 (100)
Positive 256 (49.2) 34 (57.6) 36 (50.7) 81 (32.5) 0 (0) 112 (37.6) 0 (0)
Distant metastasis
Negative 491 (94.4) 57 (96.6) – – – – –
Positive 15 (2.9) 1 (1.7) – – – – –
TNM stage
I 89 (17.1) 13 (22.0) – – – – –
II 290 (55.8) 34 (57.6) – – – – –
III 110 (21.2) 11 (18.6) – – – – –
IV 14 (2.7) 1 (1.7) – – – – –
Tumour grade
Grade 1 – – 7 (9.9) 68 (27.3) 29 (14.5) – –
Grade 2 – – 25 (35.2) 126 (50.6) 136 (68.0) – –
Grade 3 – – 36 (50.7) 55 (22.1) 35 (17.5) – –
ER status
Negative 117 (22.5) 9 (15.3) 18 (25.4) 34 (13.7) – 0 (0) 77 (26.9)
Positive 396 (76.2) 48 (81.4) 52 (73.2) 211 (84.7) – 298 (100) 209 (73.1)
PR status
Negative 176 (33.8) 16 (27.1) 22 (31.0) – – – –
Positive 336 (64.6) 41 (69.5) 48 (67.6) – – – –
HER2 status
Negative 361 (69.4) 48 (81.4) 60 (84.5) – – – –
Positive 101 (19.4) 10 (16.9) 10 (14.1) – – – –
Triple-negative
True 72 (13.8) 7 (11.9) 11 (15.5) – – – –
False 448 (86.2) 52 (89.1) 60 (84.5) – – – –
PAM50 subtype
Basal-like 96 (18.5) 11 (18.6) – – – – –
HER2-enriched 58 (11.2) 4 (6.8) – – – – –
Luminal A 231 (44.4) 32 (54.2) – – – – –
Luminal B 127 (24.4) 12 (20.3) – – – – –
Normal-like 8 (1.5) 0 (0) – – – – –
Data are presented as the number of patients in each subgroup with percentage in the parentheses. Numbers may not sum to total (N) due to missing datadata
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Reverse-transcription quantitative real-time polymerase
chain reaction
Total RNA was extracted from each specimen using
TRIzol reagent (Life Technologies), according to the
manufacturer’s instructions. RNA concentration, integ-
rity and purity were analysed using NanoDrop 1000
Spectrophotometer (Thermo Scientific) and agarose gel
electrophoresis. Quality-checked 500 ng RNA per speci-
men was reverse transcribed using high capacity RNA-
to-cDNA kit (Life Technologies) in a final reaction
volume of 12 μL containing random hexamer primers.
The incubation conditions for reverse transcription (RT)
were: 37 °C for 60 min, 95 °C for 10 min and hold at
4 °C indefinitely. RT-negative controls (reactions with
no reverse transcriptase) of two RNA samples were
prepared for testing DNA contamination. The cDNA
was kept at −20 °C until used for quantitative real-
time PCR (qPCR).
The qPCR was performed using SYBR Green PCR
master mix (Life Technologies) in MicroAmp optical
384-well reaction plates (Life Technologies) on an
Applied Biosystems 7900HT Fast Real-Time PCR
System. The primers for qPCR were designed using
AlleleID 7.6 (PREMIER Biosoft) to span at least one
exon-exon junction and to cover all the transcript
variants found in Entrez Gene (Table 2). Each qPCR
reaction had a total volume of 10 μL that contained
12.5 ng cDNA templates, 200 nM forward primers, 200
nM reverse primers and 5 μL SYBR Green PCR master
mix. The thermal cycling conditions were: 95 °C for
10 min, followed by 40 cycles of 95 °C for 15 s and 60 °
C for 1 min, and a dissociation stage. The qPCR reac-
tions containing the same cDNA template with the
whole set of qPCR primer pairs were run on the same
plate to avoid assay variability. Every combination of
cDNA template and qPCR primer pairs was tested in
triplicate. Each qPCR product was verified by dissoci-
ation curve analysis, and all the qPCR products of two
cDNA templates were verified by 2.2 % agarose gel elec-
trophoresis that showed single band with correct ampli-
con length and no primer dimmer. There was no
positive amplification observed in the qPCR reactions
using the RT-negative controls as template. The thresh-
old cycle (Ct) was determined by setting the threshold to
0.1, in the exponential phase of amplification, in the
SDS 2.4 software (Life Technologies). Triplicates
with median Ct ≤30 all had SD <0.1, while those
with median Ct >30 had relatively increased SD, due
to obvious higher variability in templates with low
transcript copy-number. The median Ct for each
triplicate was obtained for further calculations. The
qPCR efficiencies of all studied genes were similar
and close to 100 %, i.e. 1 thermal cycle (expressed as
Ct) corresponds to a 2-fold change.
The 2-ΔΔCt method was used for the qPCR data
analysis [20]. GAPDH and HPRT1 were chosen as the
reference genes for normalization, as they showed
smaller SD of Ct values compared with two other puta-
tive housekeeping genes RNA18S5 and GUSB that were
assessed in our pilot study. The ΔCt for the gene of
interest was calculated by subtracting the average of Ct
for GAPDH and HPRT1 from the Ct for the gene of
interest [21]. The relative mRNA expression levels of the
genes of interest (2-ΔCt) were skewed, thus the normal-
ized and log2-transformed data, i.e. -ΔCt, was used for
data analysis [20].
Table 2 Characteristics of the primers used for RT-qPCR
Gene symbol Targeted transcript variants Primer sequences (5′ – 3′) Amplicon (bp)
TGFB1 NM_000660 (F): TCGCCAGAGTGGTTATCTT 148
(R): TAGTGAACCCGTTGATGTCC
TGFB2 NM_001135599, NM_003238 (F): ACACTCAGCACAGCAGGGTCCT 80
(R): TTGGGACACGCAGCAAGGAGAAG
TGFB3 NM_003239 (F): TGAGTGGCTGTTGAGAAGAGA 139
(R): ATTGTCCACGCCTTTGAATTTGAT
TGFBR1 NM_001130916, NM_004612 (F): GCAGAGCTGTGAAGCCTTGAGA 128
(R): TGCCTTCCTGTTGACTGAGTTG
TGFBR2 NM_001024847, NM_003242 (F): ATGACATCTCGCTGTAATGC 163
(R): GGATGCCCTGGTGGTTGA
HPRT1 NM_000194 (F): TGGCGTCGTGATTAGTGATG 160
(R): GCCTCCCATCTCCTTCATC
GAPDH NM_001256799, NM_002046 (F): TCTCTGCTCCTCCTGTTC 112
(R): CGACCAAATCCGTTGACT
F forward primer, R reverse primer, bp base pair
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Statistical analysis
Log2-transformed and normalized mRNA expression
data was used for all statistical analyses. The Wilcoxon
signed-rank test was used to test for differences in the
mRNA levels between tumours and matched normal
tissues. The Spearman’s rank correlation analysis was
employed to evaluate the correlations between the
mRNA levels of pairwise genes. The Wilcoxon rank-
sum test and Kruskal-Wallis test were employed to
test for differences in the mRNA levels in subgroups
stratified by tumour characteristics, namely, tumour
diameter, regional lymph nodes involvement, distant
metastasis, ER status, PR status, HER2 status, triple-
negative, histological type, TNM stage, tumour grade
and PAM50 subtype.
The Cox proportional hazards regression model was
used to evaluate the associations between tumour
levels of TGFB1, TGFB2, TGFB3, TGFBR1 and
TGFBR2 mRNA and patients’ overall and relapse-free
survival in the TCGA and GEO cohorts. Patient’s sur-
vival time was calculated from the date of diagnosis
to the date of event (death or relapse) or censored at
the last follow-up or last known alive time whichever
was longer. To evaluate if the tumour mRNA levels
had different associations with patients’ clinical out-
comes in the early and late years after patients were
diagnosed with breast cancer, the Cox analyses were
performed at different periods of follow-up time from
1 to 10 years. For each Cox model, the proportional
hazards assumption was evaluated, and the results
indicated that some of the gene expression variables
were time-dependent. Thus extended Cox models
using a Heaviside function approach [22] were ap-
plied to calculate the hazard ratios for the period for
0 to less than 3 years and the open-ended period
from 3 years and beyond.
To evaluate if stratifying patients by the tumour
mRNA levels would predict patients’ survival, the pa-
tients of each cohort were divided into two groups ac-
cording to their tumour mRNA levels of each gene, and
then the relevant hazard ratios for different periods of
follow-up time (from 1 to 10 years) were calculated
using Cox proportional hazards regression model. To
avoid arbitrary grouping, the cut point was set to include
10–90 % of the patients with the lowest expression in
each cohort. Representative Kaplan-Meier curves were
plotted for the cut points that produced the lowest Wald
test p-values for HR. The Likelihood-ratio test was used
to assess statistical significance of the calculated Cox re-
gression coefficients (β) and hazard ratios (HR), where β
= ln(HR). The 95 % confidence interval (CI) of HR was
calculated based on the Wald test. The Log-rank test
was used to assess significant differences between the
Kaplan-Meier estimates.
All the statistical analyses were performed using R
(version 3.2.0, R Core Team, 2015). The following R
packages were used: qvalue, GEOquery, rms, heatmap.-
plus, ggplot2, gplots, gridExtra and reshapes2. All the p-
values (P) presented were two-sided, and the significance
level was set at 0.05. Bonferroni correction for multiple
testing was applied where appropriate and corrected p-
values were given the symbol P’. For comparison,
Storey’s false discovery rate (FDR) procedure, a less
stringent multiple testing correction method, was also
applied where appropriate [23].
Results
The bio-specimens from the TCGA, GEO and RT-qPCR
cohorts were all collected from newly diagnosed patients
with breast tumours that had received no prior treatment,
such as chemotherapy or radiotherapy. The clinical, patho-
logical and molecular characteristics of the breast cancer
specimens were summarised in Table 1. The population of
tumours from the TCGA cohort was not significantly
different from the TCGA sub-cohort that contained
adjacent normal tissues and the RT-qPCR cohort in terms
of the tumour characteristics, with the only exception being
“tumour diameter” (Fisher’s exact test P = 3.6 × 10−6), in
which the tumours from TCGA were overall larger than
the tumours from the local tissue banks.
Comparison of mRNA levels between primary breast
tumours and adjacent normal tissues
Significantly higher TGFB1 and TGFB3 mRNA levels
and lower TGFBR2 mRNA levels were observed in the
primary breast tumours compared with their matched
normal tissues (Fig. 1). Higher variance of TGFB2 mRNA
levels was observed compared with the other genes.
TGFβ1 and TGFβ3 are generally considered more alike
Fig. 1 Comparison of mRNA levels between primary breast
tumours and adjacent normal tissues. The mRNA expression
levels (log2-transformed and median-centred) of TGFB1, TGFB2,
TGFB3, TGFBR1 and TGFBR2 were compared between 59 primary
breast tumours and their adjacent normal tissues from the TCGA
cohort using a the Wilcoxon signed-rank test. b Bonferroni cor-
rected p-values. c The relative median mRNA expression levels in
cancer versus normal tissues
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than either is compared to TGFβ2 in term of functions,
given that TGFβ1 and TGFβ3 are capable of binding
directly to TβRII, while TGFβ2 binds TβRII weakly and is
dependent upon the co-receptor betaglycan for function
[24]. Interestingly, positive correlations between the mRNA
levels of TGFBR2 and the mRNA levels of TGFB1
(Spearman’s rho = 0.51, P = 5.6 × 10−5, P’ = 5.6 × 10−4) and
TGFB3 (Spearman’s rho = 0.42, P = 0.0012, P’ = 0.012) were
observed in the tumours (n = 59).
Associations between tumour mRNA levels and tumour
characteristics
The associations between the mRNA levels of TGFB1,
TGFB2, TGFB3, TGFBR1 and TGFBR2 and the tumour
characteristics displayed in Table 1 were evaluated using
Wilcoxon rank-sum test and Kruskal-Wallis test. The
significant associations that were observed from both of the
TCGA and RT-qPCR cohorts were shown in Fig. 2. The
mRNA levels of TGFB3 was significantly lower in the ER-
negative, PR-negative and triple-negative tumours (Fig. 2b,
c and f). It was also shown that TGFB3 mRNA had signifi-
cantly the lowest expression in the Grade 3 tumours
(Fig. 2g), which agreed with a few studies evaluating the
mRNA and protein levels of TGFB3 [25, 26]. Seemly lower
TGFB1 mRNA levels were observed in the tumours from
regional lymph node-negative patients and in the triple-
negative tumours, and lower TGFBR1 mRNA levels were
observed in HER2 negative tumours (Fig. 2a, d and e),
Fig. 2 Associations between tumour mRNA levels and tumour characteristics. The mRNA expression levels (log2-transformed and median-centred)
of TGFB1, TGFB2, TGFB3, TGFBR1 and TGFBR2 (labels on y-axis) were compared between different subgroups of breast tumours (grouped by tumour characteristics,
labels on x-axis) from different cohorts (titles on each panel). The analysis were initially performed in the TCGA cohort or in the GEO cohort, and the tests with
p-values <0.05 were verified in the RT-qPCR cohort. Comparison of tumour TGFB1mRNA levels by (a) regional lymph node status and (e) triple-negative status.
Comparison of tumour TGFB3mRNA levels by (b) ER status, (c) PR status, (f) triple-negative status and (g) tumour grade. Comparison of tumour TGFBR1mRNA
levels by (d) HER2 status. The number of patients (n) of each tumour subgroup was shown under each boxplot. The estimated relative mRNA expression levels
(Fold) in the tumour subgroup on the right side in each panel (Positive, False or grade 3, presented as white boxplot) versus the one on the left side (Negative,
True or grade 2, presented as grey boxplot), 95 % confidence intervals and p-values were calculated from the Wilcoxon rank-sum test. a The data presented were
standardized, thus no fold change was calculated. b The relevant values were calculated for grade 2 and grade 3 tumours
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though the corresponding p-values did not survive Bonfer-
roni correction.
All the five genes were expressed to variable levels
across different PAM50 subtypes, and exhibited hetero-
geneous expression profiles within each PAM50 subtype
(Fig. 3). For example, in the Luminal A subtype, some
tumours had high expression of all five genes while some
had low expression of all five genes. Significantly lower
expression of TGFB3 was observed in the Basal-like tu-
mours, which was in agreement with that the lower ex-
pression of TGFB3 was associated with ER, PR-negative
tumours and that most of the Basal-like tumours were
ER, PR-negative (Fig. 3). TGFBR2 had the highest me-
dian expression levels in the Normal-like subtype (Fig. 3),
which was in concordance with the result that TGFBR2
was significantly down-regulated in the tumours com-
pared with their adjacent normal tissues (Fig. 1).
Associations between tumour mRNA levels and patients’
clinical outcomes
Higher TGFB2 mRNA levels in the primary tumours
were associated with better overall survival of patients
(Fig. 4a). The beneficial effect of having higher expres-
sion of TGFB2 mRNA in the tumours seemed to be in
the later years after diagnosis (Fig. 5a). In the patients,
the hazard ratio of death for having tumours expressing
the highest 60 % of TGFB2 mRNA levels versus having
tumours expressing the lowest 40 % of TGFB2 mRNA
levels for the first 9 years after diagnosis was 0.5 (95 %
CI: 0.31 – 0.81, Fig. 6c). Although the p-value did not
survive Bonferroni correction, it had a q-value of 0.02
representing 2 % of FDR.
Higher TGFB3 mRNA levels in the primary tumours
were associated with better relapse-free survival of pa-
tients, especially for the lymph node-negative patients
and in the first 3 years after diagnosis (Figs. 4b and 5b).
In patients diagnosed with lymph node-negative tu-
mours, compared with those whose breast tumours were
in the lowest 10 % of TGFB3 expression, the other 90 %
patients had significantly better relapse-free survival
for the first 2 years (P = 1.6 × 10−6, P’ = 1.4 × 10−4)
with HR = 0.3, 95 % CI: 0.18 – 0.51 (Fig. 6e).
Higher TGFBR1 mRNA levels were associated with
poorer overall survival in the first 3 years, especially for
the patients with small (diameter ≤2 cm) tumours
(Figs. 4a and 5a). This finding was consistent with de
Kruijf et al.’s study evaluating the protein levels of TβRI
by immunohistochemistry [9]. The authors also reported
that high TβRII expression was associated with an un-
favourable prognosis concerning progression-free sur-
vival. Whereas, it was shown in this study that higher
TGFBR2 mRNA expression was associated with better
relapse-free survival for patients, especially for those
with negative lymph node status and in the first 3 years
(Figs. 4b, 5b and 6f). This finding was more in agree-
ment with Paiva et al.’s study which showed that TβRII
down-expression was significantly associated with breast
cancer and the absence of TβRII was an adverse prog-
nostic factor [10].
Discussion
TGFβ signalling is well known for its involvement in a
wide range of different, even opposite cellular processes,
such as those involved in tumour suppression and
tumour progression [4]. Tumour cells that have accumu-
lated mutations to circumvent the suppressive effect of
TGFβ may not only withstand a TGFβ-rich micro-
environment but also exploit the TGFβ signalling machin-
ery for malignant progression [1]. Thus we may assume
Fig. 3 Heatmap visualization of tumour mRNA levels. Tumour samples
from the TCGA cohort were hierarchically clustered according to the
log2-transformed and standardized mRNA expression levels of TGFB1,
TGFB2, TGFB3, TGFBR1 and TGFBR2 for each PAM50 subtype in the
middle panel, where each row represented a tumour specimen and
each column represented a gene. The colour represented the mRNA
expression levels (green: low, red: high). The median mRNA levels of
each gene for each PAM50 subtype were shown at the bottom, and
the p-values were calculated from the Kruskal-Wallis test for differences
in the mRNA levels across the PAM50 subtypes. All the p-values were
still significant after Bonferroni correction for multiple testing. The
tumour diameter (T), lymph node metastasis (N), distant metastasis (M),
ER PR and HER2 statuses of each specimen were shown in the
right-side columns, white: positive or >2 cm, black: negative
or ≤2 cm, grey: missing data
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that there are generally three types of tumour cells in terms
of their responses to TGFβ: those that respond to TGFβ
and are suppressed (type 1), those that do not respond to
TGFβ (type 2) and those that respond to TGFβ but
progress (type 3).
In breast cancer, mutations are rarely found in the TGFβ
family genes [27], which implicates that the cellular
context rather than the proteins in the TGFβ signalling
pathway determines the action of TGFβ [4]. Thus the
levels of biologically active forms of TGFβ ligands in the
microenvironment and the protein expression levels of
TGFβ receptors may serve as quantitative measures of the
intensity of TGFβ signalling input and the responsiveness
of cells to TGFβ, respectively. The protein expression
levels of the TGFβ ligands may be used as the estimates of
the levels of their biologically active forms, since all the
TGFβ isoforms are expressed as latent forms that need to
be activated to function [28]. The mRNA expression levels
may be used as the estimates of the protein expression
levels [29].
The TGFBR2 mRNA levels were reduced by around
two-thirds in breast tumours compared with matched
normal tissues, which was consistent with a study
evaluating the protein levels of TβRII [30]. The result
implicated that the breast tumour cells had developed
abilities to reduce their responsiveness to TGFβ by
down-regulating TGFBR2 expression. Higher TGFB1
mRNA expression levels were observed in tumours
compared with adjacent normal tissues and seemly in
tumours from lymph node-positive patients compared
with tumours from lymph node-negative patients. It im-
plicated that the malignant tumour cells up-regulated
Fig. 4 Associations between tumour mRNA levels and patients’ clinical outcomes. a The associations between primary breast tumour mRNA
levels of TGFB1, TGFB2, TGFB3, TGFBR1 and TGFBR2 and patients’ overall survival were evaluated in the TCGA cohort and its subsets stratified by
tumour diameter (T), regional lymph node status (N) and ER status using the Cox proportional hazards regression model. b Associations between
primary breast tumour mRNA levels and patients’ relapse-free survival in the GEO cohorts. The hazard ratios of death (y-axis, logarithmic scale) for
a 1-unit increase in the mRNA expression levels (log2-transformed and standardized) of the five genes for the follow-up periods from 1 to 10 years
(x-axis) were shown for each group of patients (title on each panel). The shapes were filled black if the corresponding p-values for likelihood-ratio
test were <0.05. The border of shape was coloured red if the corresponding proportional hazards assumption was not met (P <0.1). Missing data
in the first column of panel “T ≤2 cm” in panel A were due to 0 event recorded for the first year. The inserts are the same plots as the underscored
ones but having zoomed in y-axis to show the overlays
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TGFB1 expression. The TGFB3 mRNA expression levels
were around 50 % lower in the ER-negative/PR-negative/
triple-negative/Basal-like/Grade 3 tumours, which were
all associated with poor prognosis. As TGFB3 mRNA
levels were increased by 84 % in tumours compared with
adjacent normal tissues, the results should be interpreted
as TGFB3 expression was greatly up-regulated in prema-
lignant tumour cells and/or their surrounding cells (the
bio-specimens were usually composed of <100 % tumour
cells), rather than TGFB3 expression was down-regulated
in malignant tumour cells. The up-regulated TGFB1 ex-
pression in malignant tumour cells and the up-regulated
TGFB3 expression in premalignant tumour cells were very
likely to have different, even opposite effects on the corre-
sponding tumours, which also implicated the specific
biology of different TGFβ isoforms.
Assuming that we can group breast cancer patients
according to the tumour cells’ responses to TGFβ, and
evaluate the associations between the expression levels
of TGFB1, TGFB2, TGFB3, TGFBR1 and TGFBR2 and
patients’ clinical outcomes such as overall and relapse-
free survival in each group using Cox proportional
hazards regression model, then we should expect nega-
tive log hazard ratios for type 1 tumours, log HRs of
zero for type 2 tumours and positive log HRs for type 3
tumours, respectively. Obviously, the HRs for different
genes should be different. Unfortunately, we are still not
able to separate the three types of tumours. However, for
a cohort composed of patients with mixed types of
tumours, a significant negative log HR implicates that
there are more patients with type 1 tumours, a signifi-
cant positive log HR implicates that there are more
Fig. 5 Time-dependent Cox regression analysis for associations between tumour mRNA levels and patients’ clinical outcomes. a Time-dependent
Cox regression analysis for the associations between primary breast tumour mRNA levels of TGFB1, TGFB2, TGFB3, TGFBR1 and TGFBR2 and patients’
overall survival in the TCGA cohort and its subsets stratified by tumour diameter (T), regional lymph node status (N) and ER status. b Associations
between primary breast tumour mRNA levels and patients’ relapse-free survival in the GEO cohorts. A Heaviside function approach were applied
to calculate the hazard ratios of death (y-axis, logarithmic scale) for a 1-unit increase in the mRNA expression levels (log2-transformed and
standardized) of the five genes for the period for 0 to less than 3 years and the open-ended period from 3 years and beyond, for each group
of patients (title on each panel). The proportional hazards assumption was met (P ≥0.1) for each of the separate time intervals <3 years and ≥3 years.
The shapes were filled black if the corresponding p-values for likelihood-ratio test were <0.05. Missing data in the panel “ER neg.” were due to
exceeding the y-axis limit and were non-significant
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patients with type 3 tumours, and a non-significant HR
implicates that there are more patients with type 2 tu-
mours, the patients are heterogeneous or the population
is too small. Thus the association between the expres-
sion levels and patients’ clinical outcomes may serve as
an indicator of the proportion of the three types of
Fig. 6 Stratifying patients by tumour mRNA levels for prognosis. Patients were divided into two groups (low and high) according to their tumour
levels of TGFB1, TGFB2, TGFB3, TGFBR1 or TGFBR2 mRNA (a) in the TCGA cohort and its subsets and (Bb) in the GEO cohorts. To avoid arbitrary grouping,
the cut point for the percentage of patients in the group “low” was set to 10–90 % of the population with an increment of 10 % (y-axis). The hazard
ratios of event (death for the TCGA cohorts and relapse for the GEO cohorts) for the patients in group “high” compared with the patients in group
“low” for different periods of follow-up time (from 1 to 10 years, x-axis) were calculated using the Cox proportional hazards regression model. The
corresponding Cox regression coefficients (β, β = ln(HR)) with corresponding p-values for Log-rank test <0.05 were shown as heatmap (green: low, red:
high). The comparison of Kaplan-Meier estimates of survival for the arrowed data points in panels (a) and (b), which had the lowest Wald test p-values
for HR in the corresponding block, were shown in panels (c), (d), (e) and (f) accordingly. The Kaplan-Meier survival curves were shown up to 10 years
of follow-up. The statistical results shown in each plot were calculated based on different years of follow-up time as indicated by the grey dotted line.
The numbers of patients at risk were listed under each time interval
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tumours. The conflicting results such as that were re-
ported for the associations between the protein levels of
TGFβ1 and TβRII and the patients’ clinical outcomes
[8–11], were very likely due to that the studied cohorts
were composed of different proportions of the three
types of tumours.
The significant positive associations observed between
tumour levels of TGFB2, TGFB3 and TGFBR2 mRNA
and clinical outcomes in patients diagnosed with lymph
node-negative diseases implicated that the majority of
the tumours from those patients still responded to the
suppressive effect of TGFβ signalling, and the tumours
with lower TGFB2, TGFB3 and TGFBR2 expression were
more advantageous in tumour progression. In patients
diagnosed with small tumours, those with higher
TGFBR1 mRNA levels in the tumours had much poorer
prognosis for the first 3 years. One of the rationales
for anti-cancer drugs targeting the TGFβ pathway is
to block the TGFβ signalling for type 3 tumours but
not type 1 or type 2 tumours. Our data implicated
that in the patients with small breast tumours, there
was a high proportion of patients with type 3 tu-
mours that might be more likely to benefit from the
drugs targeting TβRI.
Conclusion
In conclusion, the mRNA levels of the TGFβ isoforms
and receptors in breast tumours were differentially asso-
ciated with patients’ overall and relapse-free survival in
patients stratified by different tumour characteristics.
Before we can develop techniques to precisely classify
breast tumours into different types according to their re-
sponses to TGFβ, the associations between the tumour
mRNA levels and patients’ clinical outcomes may not
only provide prognostic value for patients but also assist
in classifying tumours according to their potential re-
sponses to TGFβ and selecting patients for the TGFβ
signalling pathway targeted therapies that are under de-
velopment [6]. The mechanisms underlying the reduced
TGFBR2 expression in tumours and the differentially
regulated TGFB1 and TGFB3 expression by malignant
and premalignant tumour cells may also have potential
clinical implications that need to be further explored.
Competing interests
The authors declare no potential conflicts of interests.
Authors’ contributions
LV, KNZ, PPM, PTS and CC contributed to the conception and design of the
study. AA prepared 32 breast tumour specimens. PTS and SRL prepared 39 RNA
of breast tumour specimens. CC designed and performed the experiments,
collected the data, conducted the data analysis and interpretation, and wrote
the manuscript. All authors critically reviewed the manuscript and approved the
final version for publication.
Acknowledgments
We thank the patients and their families for the tissues donated for research.
LV has received National Institute of Complementary Medicine and National
Health and Medical Research Council of Australia competitive funding and
Industry support for research into nutraceuticals used for chronic diseases.
PTS is a recipient of a fellowship from the National Breast Cancer
Foundation, Australia. CC has received a research scholarship from a grant
awarded to LV by the National Institute of Complementary Medicine and
National Health and Medical Research Council of Australia via the Centre
for Integrative Clinical and Molecular Medicine, School of Medicine at The
University of Queensland.
Author details
1The University of Queensland, School of Medicine, Level 5, Translational
Research Institute, 37 Kent Street, Woolloongabba, Brisbane, QLD 4102,
Australia. 2The University of Queensland, UQ Centre for Clinical Research,
Brisbane, Australia. 3Pathology Queensland, The Royal Brisbane & Women’s
Hospital, Brisbane, Australia. 4QIMR Berghofer Medical Research Institute,
Brisbane, Australia. 5Medlab Clinical, Sydney, Australia. 6The University of
Sydney, Sydney Medical School, Sydney, Australia.
Received: 10 January 2014 Accepted: 10 December 2015
References
1. Massague J. TGFbeta in cancer. Cell. 2008;134(2):215–30.
2. Pickup M, Novitskiy S, Moses HL. The roles of TGFbeta in the tumour
microenvironment. Nat Rev Cancer. 2013;13(11):788–99.
3. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane
to the nucleus. Cell. 2003;113(6):685–700.
4. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol. 2012;
13(10):616–30.
5. Zu X, Zhang Q, Cao R, Liu J, Zhong J, Wen G, et al. Transforming growth
factor-beta signaling in tumor initiation, progression and therapy in breast
cancer: an update. Cell Tissue Res. 2012;347(1):73–84.
6. Akhurst RJ, Hata A. Targeting the TGFbeta signalling pathway in disease. Nat
Rev Drug Discov. 2012;11(10):790–811.
7. Baxley SE, Serra R. Inhibiting breast cancer progression by exploiting
TGFbeta signaling. Curr Drug Targets. 2010;11(9):1089–102.
8. Grau AM, Wen W, Ramroopsingh DS, Gao YT, Zi J, Cai Q, et al.
Circulating transforming growth factor-beta-1 and breast cancer
prognosis: results from the Shanghai Breast Cancer Study. Breast
Cancer Res Treat. 2008;112(2):335–41.
9. de Kruijf EM, Dekker TJ, Hawinkels LJ, Putter H, Smit VT, Kroep JR, et al. The
prognostic role of TGF-beta signaling pathway in breast cancer patients.
Ann Oncol. 2013;24(2):384–90.
10. Paiva CE, Drigo SA, Rosa FE, Moraes Neto FA, Caldeira JR, Soares FA, et al.
Absence of transforming growth factor-beta type II receptor is associated
with poorer prognosis in HER2-negative breast tumours. Ann Oncol.
2010;21(4):734–40.
11. Ciftci R, Tas F, Yasasever CT, Aksit E, Karabulut S, Sen F, et al. High serum
transforming growth factor beta 1 (TGFB1) level predicts better survival in
breast cancer. Tumour Biol. 2014;35(7):6941–8.
12. Amoils KD, Bezwoda WR. TGF-beta 1 mRNA expression in clinical breast
cancer and its relationship to ER mRNA expression. Breast Cancer Res Treat.
1997;42(2):95–101.
13. MacCallum J, Bartlett JM, Thompson AM, Keen JC, Dixon JM, Miller WR.
Expression of transforming growth factor beta mRNA isoforms in human
breast cancer. Br J Cancer. 1994;69(6):1006–9.
14. Cancer Genome Atlas N. Comprehensive molecular portraits of human
breast tumours. Nature. 2012;490(7418):61–70.
15. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al.
Supervised risk predictor of breast cancer based on intrinsic subtypes.
J Clin Oncol. 2009;27(8):1160–7.
16. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, et al.
Genetic reclassification of histologic grade delineates new clinical subtypes
of breast cancer. Cancer Res. 2006;66(21):10292–301.
17. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, et al.
The humoral immune system has a key prognostic impact in node-negative
breast cancer. Cancer Res. 2008;68(13):5405–13.
Chen et al. BMC Cancer  (2015) 15:1010 Page 11 of 12
18. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al.
Gene-expression profiles to predict distant metastasis of lymph-node-
negative primary breast cancer. Lancet. 2005;365(9460):671–9.
19. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, et al.
Genomic index of sensitivity to endocrine therapy for breast cancer.
J Clin Oncol. 2010;28(27):4111–9.
20. Yuan JS, Reed A, Chen F, Stewart Jr CN. Statistical analysis of real-time PCR
data. BMC Bioinformatics. 2006;7:85.
21. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A,
et al. Accurate normalization of real-time quantitative RT-PCR data by
geometric averaging of multiple internal control genes. Genome Biol.
2002;3(7):RESEARCH0034.
22. Kleinbaum DG, Klein M. Extension of the cox proportional hazards model
for time-dependent variables. Stat Biol Health. 2012:241–288. DOI 10.1007/
978-1-4419-6646-9_6
23. Storey JD. A direct approach to false discovery rates. J R Stat Soc B.
2002;64:479–98.
24. De Crescenzo G, Hinck CS, Shu Z, Zuniga J, Yang J, Tang Y, et al.
Three key residues underlie the differential affinity of the TGFbeta isoforms
for the TGFbeta type II receptor. J Mol Biol. 2006;355(1):47–62.
25. Laverty HG, Wakefield LM, Occleston NL, O’Kane S, Ferguson MW. TGF-beta3
and cancer: a review. Cytokine Growth Factor Rev. 2009;20(4):305–17.
26. Figueroa JD, Flanders KC, Garcia-Closas M, Anderson WF, Yang XR, Matsuno
RK, et al. Expression of TGF-beta signaling factors in invasive breast cancers:
relationships with age at diagnosis and tumor characteristics. Breast Cancer
Res Treat. 2010;121(3):727–35.
27. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al.
Mutational landscape and significance across 12 major cancer
types. Nature. 2013;502(7471):333–9.
28. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation.
J Cell Sci. 2003;116(Pt 2):217–24.
29. Vogel C, Marcotte EM. Insights into the regulation of protein
abundance from proteomic and transcriptomic analyses.
Nat Rev Genet. 2012;13(4):227–32.
30. Gobbi H, Arteaga CL, Jensen RA, Simpson JF, Dupont WD, Olson SJ, et al.
Loss of expression of transforming growth factor beta type II receptor
correlates with high tumour grade in human breast in-situ and invasive
carcinomas. Histopathology. 2000;36(2):168–77.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Chen et al. BMC Cancer  (2015) 15:1010 Page 12 of 12
